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2584Letters to the EditorThe MOGE(S)
Classiﬁcation for a
Phenotype-Genotype
Nomenclature of Cardiomyopathy
More Questions Than Answers?I appreciate the recent paper by Arbustini et al. (1) in which they
propose a descriptive nosology that combines morphofunctional
trait and organ/system involvement with familial inheritance
pattern, identiﬁed genetic defect, or other etiologies. In my
opinion, a real revolution for clinical geneticists was the introduc-
tion of the concept of diagnostic “red ﬂags” made by Dr. Arbustini,
clinical markers that can guide the genetic research to a speciﬁc
gene (for example, atrioventricular block for the lamin A/C gene or
increased serum creatine phosphokinase for dystrophin gene
defects). On the basis of these red ﬂags, the authors proposed this
new classiﬁcation, which is much more detailed with respect to the
previous American and European attempts (2,3).
This new approach seems to be useful for many inherited car-
diomyopathies but, as underlined by the editorial by Elliott (4),
it is difﬁcult to apply to arrhythmogenic right ventricular dysplasia/
cardiomyopathy, because even the epsilon wave, which was for
many years considered the marker of the disease, can represent a red
ﬂag only when it is present at electrocardiography. Nowadays, it is
clear that the diagnosis of right ventricular dysplasia/cardiomyopathy
requires several red ﬂags (4,5). Finally, I hope that this new classiﬁ-
cation will open the doors to the unresolved problem of phenotype-
genotype correlation, considering ﬁrst of all families carrying the
same mutation; only in this case, I think it will be possible to use the
genetic data for the prognosis and therapy of inherited cardiomy-
opathies, even if it is well-known that many mutations are “private.”*Michele Pasotti, MD, PhD
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Circulation 2000;101:E101–6.ReplyThe MOGE(S) Classiﬁcation
for a Phenotype-Genotype
Nomenclature of Cardiomyopathy
More Questions Than Answers?Dr. Pasotti, as most other cardiologists with expertise in cardio-
myopathies do (1), so aptly perceives the need for a more
comprehensive classiﬁcation that describes the phenotype and the
related “red ﬂag” involvement of other organs, and genetic (or
nongenetic) basis of the disease and supports the attempt of the
nosology proposed by MOGE(S) (morphofunctional characteristics
[M], organ involvement [O], genetic or familial inheritance pattern
[G], and an explicit etiological annotation [E], with details of ge-
netic defects or underlying disease cause [S]) (2). As commented by
Elliott (3) on the application of MOGE(S) (2), arrhythmogenic
right ventricular dysplasia/cardiomyopathy (ARVC/D) matches the
complexity of a disease in which the diagnostic criteria have been
debated and modiﬁed. In the original deﬁnition, the ARVC/D
was typically a right ventricular cardiomyopathy (4). The recently
modiﬁed Task Force Criteria recognizes ARVC/D as classic right
(the most common), biventricular, or predominantly left types (5).
The diagnosis relies on the demonstration of structural, func-
tional, and electrophysiological abnormalities that are caused by
or reﬂect the underlying histological changes. In both the original
and revised criteria, imaging-based morphological and functional
data (i.e., right ventricular size, akinesia, dyskinesia, or aneurysm,
dyssynchronous right ventricular contraction) remain the major
diagnostic contributors. In the routine clinical practice, the echo-
cardiographic or cardiac magnetic resonance (CMR) information
are, along with electrocardiographic features, the major alerting
traits. In the revised criteria, deﬁnite diagnosis is entertained when
2 major (M), or 1 major and 2 minor (m) criteria, or 4 minor cri-
teria from different categories are present, and the diagnosis of
the borderline ARVC/D is made when 1 major and 1 minor, or 3
minor criteria from different categories are present. A diagnosis of
possible ARVC/D is made if 1 major or 2 minor criteria from
different categories are observed. The application of these criteria
Figure 1 Pedigree Showing a Family With Autosomal Dominant ARVC Associated With a Frameshift Mutation in PKP2 Gene
The proband (III:2, arrow), asymptomatic, was brought to clinical attention because of electrocardiographic changes for sport suitability. At baseline, we documented 2 major
criteria (regional dysfunction by echocardiography/cardiac magnetic resonance, and repolarization abnormalities on an electrocardiogram [ECG]) and 1 minor criterion
(arrhythmia, >500 VPC/24 h); MOGE(S) generated as MA(M2þm1)OHGUEG-NA-SA-I. After family screening and genetic testing, another major criterion (a pathological mutation in
PKP2 and positive family history) was added (revised MOGE[S] MA(M3þm1)OHGADEG-NA-PKP2[p.Lys672ArgfsX12]SA-I). At family screening, relatives II:2, III:4, and III:3 were affected. The
relatives I:2 and II:7, who had died suddenly, were obligate carriers of the PKP2 mutation; the family member II:3 had a clinical diagnosis of dilated cardiomyopathy and died at
43 years of age while waiting for heart transplantation. II:3 did not have genetic testing or an autopsy. The 3 panels below the pedigree chart show the ECGs of III:2, III:3, and
III:4. Below each ECG, the MOGE(S) nosology was generated by using the app (http://moges.biomeris.com/moges.html). ARVC ¼ arrhythmogenic right ventricular dysplasia/
cardiomyopathy; DCM ¼ dilated cardiomyopathy; LBBB ¼ left bundle branch block; NSVT ¼ nonsustained ventricular tachycardia; RV ¼ right ventricular; SD ¼ sudden
death; þ ¼ carrier of the mutation; wt ¼ wild type.
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2585could be relatively simple in MOGE(S) (2). We emphatically
insisted in our presentation (3) that the proposed classiﬁcation
is ﬂexible and allows easy modiﬁcation to the MOGES app. In
the case of ARVC/D, we may use M for major and m for minor;
the minor criteria can be further speciﬁed as m33 (3 minor
criteria from 3 categories) or m32 (3 minor criteria from 2
categories). The following examples have been generated with the
MOGES app (http://moges.biomeris.com/moges.html) and refer
to Figure 1.
Family member III:2
– MA(M3þm1)OHGADEG-PKP2[p.Lys672ArgfsX12]SA-I
Family member III:3
– MA(M1þm2x2)OHGADEG-PKP2[p.Lys672ArgfsX12]SA-IFamily member III:4
– MA(M2þm1)OHGADEG-PKP2[p.Lys672ArgfsX12]SA-I
In day-to-day clinical practice, the difﬁculty may arise when
one encounters incidental electrocardiographic abnormalities in
asymptomatic individuals with noncontributory echocardiog-
raphic or cardiac magnetic resonance ﬁndings, 2-h ambulatory
Holter monitoring information, and a negative family history. In
such cases, family screening (and cascade genetic testing) can
provide the deﬁnite diagnosis because a proven family history of
ARVC/D is, by itself, a major criterion. The identiﬁcation of the
mutation that causes the disease could be sufﬁcient for reaching
a deﬁnite diagnosis, especially in the youngest members of the
family, when even minor criteria are absent. Missing such a
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2586diagnosis may have serious consequences. The example of epsilon
wave reported in MOGE(S) paper was to highlight one of the
most speciﬁc markers (and a major diagnostic criterion) of the
disease (2).
Finally, the biventricular and predominantly left ventricular vari-
ants (5) as well as the less speciﬁc genetic basis of the ARVC/D
cannot be ignored. For example, ARVC/D-related desmosome gene
defects are also known to be associated with dilated cardiomyopathy
(6) and dilated cardiomyopathy–related genes such as LMNA
may also result in ARVC/D (7). Because MOGE(S) descriptors
are ﬂexible, it is rather simple to provide comprehensive informa-
tion such as MA(m43)þD(AVB) OHGADEG-LMNA[p. Lys117Arg]þ
DSC2[p.Ala596Val] SA-I, where both LMNA and PKP2 variants could
contribute to the phenotype, one to the dilated cardiomyopathy
with atro-ventricular block [LMNA p.(Lys117Arg)] and one of still
unknown pathogenicity ([DSC2 p.[Ala596Val], http://www.
arvcdatabase.info/) to the ARVC/D traits.
Taking the best from the past and approaching the future with
pragmatism would inﬂuence the quest for the development of
disease-speciﬁc, gene-based strategies for management as more
data become available to public databases. If not with MOGE(S), it
could be with any other novel system. However, any new nosology
system would not be able to ignore the consolidated proposal put
forth by the MOGE(S) nomenclature (2).Eloisa Arbustini, MD
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1744–52.Bleeding After PCI,
Vascular Access, and
Falsiﬁcation Endpoints in
Observational StudiesWe read with interest the article by Wimmer et al. (1). They
propose the use of an unexpected ﬁnding in an observational
study (that is unlikely to be causally related to the intervention
being studied) to highlight the presence of residual confound-
ing. Their strategy assumes that residual confounding accounts
for these unexpected, noncausal ﬁndings, even despite the
application of advanced and complex statistical methods to
control for confounding. However, the discovery of unexpected
results in observational studies may have other explanations
and, consequently, potentially useful applications, such as:
the search for possible alternative causal explanations, the
generation of new hypotheses, and the design of further studies
to evaluate these unexpected ﬁndings. These applications may
be useful to improve our understanding of disease pathophysi-
ology, expand the frontiers of knowledge, and ultimately
improve patient care.
From this point of view, in the present case (1), there could be
an alternative explanation for the increased bleeding rate not
apparently related to vascular access associated with femoral
percutaneous intervention (PCI); for example, the hemorrhagic
transformation of clinically unapparent embolic infarctions in
thoracoabdominal solid organs, viscera and soft tissues subsidiary
of the aortic arch, and the thoracoabdominal descending aorta.
The uneven distribution of these events according to the inter-
vention under study (femoral versus radial vascular access PCI)
could be justiﬁed by the higher probability of catheter contact
